Correlation of the acid-sensitivity of polyethylene glycol daunorubicin conjugates with their in vitro antiproliferative activity

Bioorganic and Medicinal Chemistry

Volumn 14, Issue 12, 2006, Pages 4110-4117

  Rodrigues, Paula C A ^a   Roth, Thomas ^b   Fiebig, Heinz H ^b   Unger, Clemens ^a   Mülhaupt, Rolf ^c   Kratz, Felix ^a  

^a TUMOR BIOLOGY CENTER   (Germany)

^b CHARLES RIVER LABORATORIES   (United States)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Acid sensitivity; Daunorubicin; Drug polymer conjugates; In vitro activity; Polyethylene glycol

Indexed keywords

ALPHA METHOXY POLY(ETHYLENE GLYCOL)THIOPROPIONIC ACID AMIDE; ALPHA,OMEGA BISTHIOPROPIONIC ACID AMIDE POLY(ETHYLENE GLYCOL); AMIDE; ANTINEOPLASTIC AGENT; CARBOXYLIC ACID DERIVATIVE; DAUNORUBICIN; HYDRAZONE DERIVATIVE; MACROGOL; MACROGOL 20000; MALEIMIDE DERIVATIVE; POLYMER; PROPIDIUM IODIDE; PROPIONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ASSAY; BLADDER CARCINOMA; CANCER CELL CULTURE; CELL CULTURE; CELL LINE; CHEMICAL BOND; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CONJUGATION; DRUG EFFICACY; DRUG RELEASE; ENDOCYTOSIS; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LUNG CANCER; SENSITIVITY ANALYSIS; TUMOR CELL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DAUNORUBICIN; DRUG EVALUATION, PRECLINICAL; HUMANS; HYDROGEN-ION CONCENTRATION; MOLECULAR CONFORMATION; POLYETHYLENE GLYCOLS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 33646188936     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.02.007     Document Type: Article

References (19)

1. Maeda H., Wu J., Sawa T., Matsumura Y., and Hori K. J. Control. Release 65 (2000) 271-284
2. Kratz F., Beyer U., and Schütte M.T. Crit. Rev. Ther. Drug Carrier Syst. 16 (1999) 245-288
3. Duncan R. Nat. Rev. 2 (2003) 347-359
4. Kratz F., Beyer U., Collery P., Lechenault F., Cazabat A., et al. Biol. Pharm. Bull. 21 (1998) 56-61
5. Kratz F., Beyer U., Roth T., Tarasova N., Collery P., et al. J. Pharm. Sci. 87 (1998) 338-346
6. Kratz F., Roth T., Fichtner I., Schumacher P., Fiebig H.H., et al. J. Drug Targeting 8 (2000) 305-318
7. Beyer U., Rothern-Rutishauser B., Unger C., Wunderli-Allenspach H., and Kratz F. Pharm. Res. 18 (2001) 29-38
8. Kratz F., Beyer U., Roth T., Schütte M.T., Unold A., et al. Arch. Pharm. Pharm. Med. Chem. 331 (1998) 47-53
9. Beyer U., Roth T., Schumacher P., Maier G., Unold A., et al. J. Med. Chem. 41 (1998) 2701-2708
10. Kratz F., Beyer U., Schumacher P., Krueger M., Zahn H., et al. Bioorg. Med. Chem. Lett. 7 (1997) 617-622
11. Rodrigues P.A.C., Beyer U., Schumacher P., Roth T., Fiebig H.H., et al. Bioorg. Med. Chem. 7 (1999) 2517-2524
12. Rodrigues P.C.A., Scheuermann K., Stockmar C., Maier G., Fiebig H.H., et al. Bioorg. Med. Chem. Lett. 13 (2003) 355-360
13. Riebeseel K., Biedermann E., Löser R., Breiter N., Hanselmann R., et al. Bioconjug. Chem. 13 (2002) 773-785
14. Greenwald R.B., Conover C.D., and Choe Y.H. Crit. Rev. Ther. Drug Carrier Syst. 17 (2000) 101-161
15. Dengler W.A., Schulte J., Berger D.P., Mertelsmann R., and Fiebig H.H. Anticancer Drugs 6 (1995) 522-532
16. Kratz F., Warnecke A., Scheuermann K., Stockmar C., Schwab J., et al. J. Med. Chem. 45 (2002) 5523-5533
17. Kratz F., Warnecke A., Schmid B., Chung D., and Gitzel M. Curr. Med. Chem.-Anti-Cancer Agents 13 (2005) 763-771
18. Gmehling D., Medinger M., Mross K., Haering B., Kratz F., et al. Proc. Am. Assoc. Cancer Res. 46 (2005) 3987
19. clinicaltrials@seagen.com.